Juno Therapeutics (JUNO) Misses Q3 EPS by 2c
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Juno Therapeutics (NASDAQ: JUNO) reported Q3 EPS of ($0.57), $0.02 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $10.63 million.
Cash, cash equivalents, and marketable securities as of September 30, 2016 were $1.04 billion compared to $1.11 billion as of June 30, 2016 and $1.22 billion as of December 31, 2015.
Juno Therapeutics reaffirmed FY2016 guidance.
For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canadian Pacific Railway (CP) Tops Q4 EPS by CAD$0.23
- Boston Private Financial (BPFH) Tops Q4 EPS by 3c
- Simmons First National Corp (SFNC) Tops Q4 EPS by 8c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!